Pomalidomide Shows Benefits in Trials Testing New Combinations
January 20th 2015Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.
Read More